- Home
- CISS vs VBIO Comparison
CISS vs VBIO Comparison
Compare CISS & VBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CISS | VBIO |
|---|---|---|
| Founded | 2022 | N/A |
| Country | Greece | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7M | 1.6M |
| IPO Year | 2022 | 2021 |
Fundamental Metrics
Financial Performance| Metric | CISS | VBIO |
|---|---|---|
| Price | $1.23 | $2.07 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 1.4M | ★ 6.5M |
| Earning Date | 05-19-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $780,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $0.82 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.06 | $0.11 |
| 52 Week High | $6.06 | $4.14 |
Technical Indicators
Market Signals| Indicator | CISS | VBIO |
|---|---|---|
| Relative Strength Index (RSI) | 45.78 | 54.90 |
| Support Level | $0.76 | $0.25 |
| Resistance Level | $1.89 | $4.14 |
| Average True Range (ATR) | 0.21 | 0.59 |
| MACD | -0.09 | -0.03 |
| Stochastic Oscillator | 0.00 | 50.60 |
Price Performance
Historical ComparisonAbout CISS C3is Inc.
C3is Inc is a provider of international seaborne transportation services to dry bulk charterers, including national and private industrial users, commodity producers, and traders. The company owns and operates a fleet of two dry bulk carriers that transport bulk commodities such as iron ore, coal, and grains, and minor bulks such as bauxite, phosphate, and fertilizers.
About VBIO Valion Bio Inc. Common Stock
Valion Bio Inc is a late-stage biopharmaceutical company developing biologics that activate innate immune pathways for cytoprotection and immune modulation. Its main candidate, Entolimod, is a TLR5 agonist and also advances Entolasta, a next-generation TLR5 agonist, and targets the neutropenia oncology supportive care market.